Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase 2 Clinical Study of Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

NCT05953545 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.

NCT NCT05953545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05953545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase 2 Clinical Study of Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase
Phase 2
Overall status
Withdrawn
Start date
May 22, 2024
Completion date
May 22, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis delta